Otonomy, Inc. (OTIC)

NASDAQ: OTIC · Delayed Price · USD
1.99
-0.04 (-1.97%)
At close: Jan 18, 2022 4:00 PM
2.01
0.02 (1.01%)
After-hours:Jan 18, 2022 6:58 PM EST
Market Cap112.80M
Revenue (ttm)178,000
Net Income (ttm)-48.25M
Shares Out56.68M
EPS (ttm)-0.81
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Open2.03
Previous Close2.03
Day's Range1.98 - 2.07
52-Week Range1.14 - 5.73
Beta1.76
AnalystsStrong Buy
Price Target6.30 (+216.6%)
Earnings DateNov 10, 2021

About OTIC

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinica...

IndustryPharmaceuticals
IPO DateAug 13, 2014
CEODavid Weber
Employees56
Stock ExchangeNASDAQ
Ticker SymbolOTIC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Otonomy stock is "Strong Buy." The 12-month stock price forecast is 6.30, which is an increase of 216.58% from the latest price.

Price Target
$6.30
(216.58% upside)
Analyst Consensus: Strong Buy

News

Otonomy Reports Corporate and Product Pipeline Update

Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss  expected during 2022

1 week ago - GlobeNewsWire

Otonomy to Participate in the H.C. Wainwright BioConnect Conference

SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its partic...

2 weeks ago - GlobeNewsWire

Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its partic...

2 months ago - GlobeNewsWire

Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates

Otonomy (OTIC) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET

2 months ago - GlobeNewsWire

Otonomy to Report Third Quarter 2021 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will re...

2 months ago - GlobeNewsWire

Otonomy (OTIC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the public...

3 months ago - GlobeNewsWire

Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prese...

3 months ago - GlobeNewsWire

Otonomy to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that mana...

4 months ago - GlobeNewsWire

Otonomy Appoints Jill Broadfoot to Board of Directors

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appoin...

5 months ago - GlobeNewsWire

Otonomy (OTIC) Reports Q2 Loss, Lags Revenue Estimates

Otonomy (OTIC) delivered earnings and revenue surprises of -11.76% and -46.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET

5 months ago - GlobeNewsWire

Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will re...

5 months ago - GlobeNewsWire

Will Otonomy (OTIC) Report Negative Q2 Earnings? What You Should Know

Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initia...

7 months ago - GlobeNewsWire

Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows

Otonomy Inc (NASDAQ: OTIC) may have hit a snag with the development of its lead ear disorder candidate Otividex. Still, the company is trumpeting an early win for a gene therapy designed to treat congen...

8 months ago - Benzinga

Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency OTO-825 administration rescues hearing and cochlear damage in tw...

8 months ago - GlobeNewsWire

Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET

8 months ago - GlobeNewsWire

Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update

SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will rep...

8 months ago - GlobeNewsWire

Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

AAV-mediated gene therapy rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency AAV-mediated gene therapy rescues hearing and cochlear damage...

8 months ago - GlobeNewsWire

Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closi...

9 months ago - GlobeNewsWire

Otonomy Announces Pricing of $30.1 Million Public Offering

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prici...

9 months ago - GlobeNewsWire

Otonomy Announces Proposed Public Offering

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it h...

9 months ago - GlobeNewsWire

Otonomy to Present at the Needham Virtual Healthcare Conference

SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its parti...

9 months ago - GlobeNewsWire